



LABORATORY REPORT

QC ACCOUNT (WARDE)
300 W. TEXTILE
ANN ARBOR MI 48108

EXAMPLE, REPORT
WX0000003481 F 12/08/1988 34 Y

Referral Testing

Collected: 10/01/2021 11:14 Received: 10/01/2021 11:14

Test Name Result Flag Ref-Ranges Units Site

Acute Myeloid Leukemia Prognostic Panel (Normal Karyotype)

Specimen Source Blood QCRL
Sample ID 123456 QCRL
CEBPA Mutation NOT DETECTED QCRL

Reference Range:
NOT DETECTED

Test Performed at:
Quest Diagnostics Nichols Institute
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042 I Maramica MD, PhD, MBA

NPM Mutation, Cell-based NOT DETECTED QCRL

Reference Range:
NOT DETECTED

A mutation at exon 12 of the NPM gene is a predictor of favorable prognosis in acute myeloid leukemia (AML) cases with a normal karyotype; it is also an indication of good response to induction chemotherapy.

This assay can detect 5% of mutant cells in the background of wildtype cells. The PCR amplification was performed using NPM intron 11 forward primer and 6-fam-labeled NPM exon 12 reverse primer. The wildtype displayed a 212bp peak, while the NPM mutant displayed a 216bp peak in addition to the NPM wildtype peak. The % of mutant to total (peak height) will be reported.

This test is performed pursuant to a license agreement with Roche Molecular Systems, Inc.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Test Performed at:
Quest Diagnostics Nichols Institute
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042 I Maramica MD, PhD, MBA

FLT3 ITD NOT DETECTED QCRL

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



LABORATORY REPORT

QC ACCOUNT (WARDE)
300 W. TEXTILE
ANN ARBOR MI 48108

EXAMPLE, REPORT
WX0000003481 F 12/08/1988 34 Y

Referral Testing

Collected: 10/01/2021 11:14 Received: 10/01/2021 11:14

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Rows include FLT3 TKD, FLT3 ITD Size, FLT3 ITD Allelic Ratio, and FLT3 TKD Allelic Ratio.

FLT3 mutations have been described in approximately 30% of acute myeloid leukemia cases. Both ITD and TKD mutations activate FLT3 kinase activity and promote malignancy.

For additional information, please refer to https://education.questdiagnostics.com/faq/FAQ221 (This link is being provided for informational/educational purposes only.)

Genomic DNA was extracted from the patient sample and tested for the presence of FLT3 gene ITD (Internal Tandem Duplication) and TKD (Tyrosine Kinase Domain) mutations.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA.

Test Performed at: Quest Diagnostics Nichols Institute 33608 Ortega Highway

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



LABORATORY REPORT

QC ACCOUNT (WARDE)
300 W. TEXTILE
ANN ARBOR MI 48108

EXAMPLE, REPORT
WX0000003481 F 12/08/1988 34 Y

Referral Testing

Collected: 10/01/2021 11:14 Received: 10/01/2021 11:14

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: San Juan Capistrano, CA 92675-2042, I Maramica MD, PhD, MBA, Reported Date: 10/01/2021 11:21, ACMYL

Performing Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

D001000007 Ordered By: CLIENT CLIENT
WX0000003481 WX00000000002063
Printed D&T: 11/30/23 09:19

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 3 OF 3